Dosage protocol · Metabolic & Weight Loss

Tirzepatide 30 mg

Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).

  • Reconstitute: Add 3.0 mL bacteriostatic water → 10.0 mg/mL concentration.
  • Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).
  • Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.
BAC water3.0mL
Concentration10.0mg/mL
Per unit (0.01 mL)100mcg

Reconstitution

Tirzepatide dosage chart

Tirzepatide dosage chart
30 mgFor research & educational use only.
PhaseWeekDraw
Weeks 1–42.5 mg 25 units × 1 injection0.25 mL
Weeks 5–85 mg 50 units × 1 injection0.50 mL
Weeks 9–127.5 mg 75 units × 1 injection0.75 mL
Weeks 13–1610 mg 100 units × 1 injection1.0 mL

How much to draw

The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.

Supplies needed

Supplies needed

Peptide vial

The lyophilized compound

Bacteriostatic water

For reconstitution

U-100 insulin syringes

One per injection

Alcohol swabs

Stopper + site each time

How it works

Tirzepatide is a synthetic peptide medication that acts as a dual agonist at two incretin hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor.[1] Incretins are gut-derived signals that help coordinate insulin release, appetite, and glucose handling after meals, and tirzepatide's engineered structure allows once-weekly subcutaneous dosing.

In the United States, tirzepatide is sold under two FDA-approved brand names with distinct indications: Mounjaro for improving glycemic control in adults with type 2 diabetes, and Zepbound for chronic weight management in adults with obesity or overweight plus a weight-related condition, as well as for moderate-to-severe obstructive sleep apnea in adults with obesity.[2] These are genuine drug approvals with full prescribing labels, not general "research peptide" status.

Benefits & side effects

The SURPASS trial program evaluated tirzepatide in type 2 diabetes; in SURPASS-2, it produced larger A1C and weight reductions than semaglutide 1 mg over 40 weeks, with gastrointestinal effects common in both groups.[4] Other SURPASS trials compared it against insulin-based regimens, generally supporting glycemic benefits in the populations studied.

For weight management, SURMOUNT-1 reported substantial dose-related weight reductions over 72 weeks in adults with obesity or overweight without diabetes, and SURMOUNT-2 extended this to people with obesity and type 2 diabetes.[5] A separate trial supporting the sleep apnea indication measured reduced apnea-hypopnea index in people with obesity. A withdrawal study (SURMOUNT-4) found people who stopped tirzepatide after initial treatment regained weight, underscoring these are treatment effects requiring continued use, not a one-time fix. Claims about anti-aging or performance enhancement are not supported by this trial base.

Calculator

Plan your own dose

Reconstituting a different vial size or targeting a different dose? Run the numbers.

1

Reconstitution

mg
mL
Concentration
Per unit (0.01 mL)
Per 10 units (0.1 mL)
2

Your dose

Doses per vial
Vial lasts
Draw to units =